Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia
BASEL, Switzerland, Nov. 18, 2024 /PRNewswire/ -- Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular malformations, today announces that the